FOLD Stock Risk & Deep Value Analysis

Amicus Therapeutics (FOLD) was acquired by BioMarin Pharmaceutical for $14.50 cash per share on April 27, 2026, leading to its delisting from Nasdaq on April 28, 2026. This fundamental change means FOLD no longer exists as an independent publicly traded entity. Consequently, it offers no future investment potential, let alone a '10x growth potential,' for new or existing investors, as shares are no longer traded and have been converted to cash at a fixed price. The previous analysis, which identified significant upside tempered by execution risk, is now entirely superseded by the acquisition event. The company's vision, competitive advantages, financial health, leadership, catalysts, and market sentiment are now integrated into BioMarin, making FOLD a non-investable entity for independent growth. **Score Change Explanation:** The previous analysis on 2025-10-05 (score 7.9/10 or 79/100) evaluated Amicus Therapeutics (FOLD) as an independent, publicly traded company with substantial 10x growth potential in rare disease markets, driven by products like Galafold and the promising AT-GAA, albeit with execution and financial sustainability risks. Since that analysis, the most material and definitive event has occurred: Amicus Therapeutics Inc. was acquired by BioMarin Pharmaceutical on April 27, 2026, at a fixed price of $14.50 per share, and its common stock has been delisted. This acquisition fundamentally alters FOLD's investment profile from a standalone growth opportunity to a non-existent public entity. The very premise of evaluating '10x growth potential' for FOLD as an independent stock is now entirely invalid. Therefore, the score has been adjusted from 79/100 to 0/100 to reflect that FOLD is no longer an investable security for future capital appreciation.